Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
- 6 May 2020
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 31 (8), 1075-1082
- https://doi.org/10.1016/j.annonc.2020.04.471
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R38HL143619)
- Eisai (R38HL143619)
- Cancer Institute NSW (R38HL143619)
- National Heart, Lung, and Blood Institute (R38HL143619)
This publication has 19 references indexed in Scilit:
- Whole-genome landscapes of major melanoma subtypesNature, 2017
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaEuropean Journal of Cancer, 2017
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2017
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisJournal of Clinical Oncology, 2017
- Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionJournal of Immunotherapy, 2017
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up GuidelinesJournal of Clinical Oncology, 2010